Reminder: Sanofi Aventis - Live Webcast: Breaking News From the American Diabetes Association 69th Scientific Sessions

September 29th, 2009 PARIS - - 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R) Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.

September 24th, 2009 PARIS - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone - 400mg Tablets). The CHMP has recommended the approval of Multaq(R) in adult clinically stable patients with history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate.

August 30th, 2009 PARIS - - SEPIA-ACS Multiple-Dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy. The results of the SEPIA-ACS1/ TIMI-42 were presented today at the plenary session of the Annual European Society of Cardiology congress in Barcelona and simultaneously published online in The Lancet.

August 29th, 2009 PARIS - - SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy. The results of the SEPIA-ACS1/ TIMI-42 were presented today at the plenary session of the Annual European Society of Cardiology congress in Barcelona and simultaneously published online in The Lancet.

July 6th, 2009 LYON, France - - Novel Vaccine IMOJEV(TM) for the Prevention of Japanese Encephalitis in Children and Adults Living in Asia Sanofi Pasteur, the vaccines division of sanofi-aventis group, (EURONEXT: SAN and NYSE: SNY), announced today that it has filed marketing authorization applications in Thailand and Australia for IMOJEV(TM), its single-dose vaccine against Japanese encephalitis (JE). This novel vaccine is aimed for the prevention of JE in children and adults living in endemic countries in Asia.

June 5th, 2009 INGELHEIM, Germany - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual Meeting (ADA) show clinically relevant and statistically significant reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels when linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, is given as add-on therapy in Type 2 diabetic patients inadequately controlled with metformin. Furthermore, these phase II study results show a placebo-like safety and tolerability profile under these therapeutic conditions.

June 2nd, 2009 PARIS and BRISBANE, California - Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage.

April 23rd, 2009 MCKINNEY, Texas - Webcast Alert: 2009 Annual Meeting of Shareholders TORCHMARK CORPORATION (NYSE: TMK) announces the following Webcast: What: 2009 Annual Meeting of Shareholders When: April 30th, 2009 @ 11:00 a.m. EDT Where: www.videonewswire.com/event.asp?id=56940 How: Live over the Internet -- Simply log on to the web at the address above.

April 20th, 2009 SINGAPORE - New Studies Advance the Development of Novel Vaccine for Dengue Prevention in Asia Pacific SINGAPORE, April 21 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today the start of clinical studies of its investigational tetravalent dengue vaccine in Singapore and Vietnam. With these studies, sanofi pasteur is expanding its global dengue vaccine clinical study program in Asia where trials are already ongoing in Thailand and the Philippines.

April 7th, 2009 PRINCETON, New Jersey - BioWa, Inc. announced today that it has entered into a license agreement with sanofi-aventis (EURONEXT: SAN and NYSE: SNY), providing the global healthcare company with access to BioWa's POTELLIGENT(R) Technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC).

June 15th, 2009 Antigenics names former Sanofi US CEO to boardLEXINGTON, Mass. — Biotechnology company Antigenics Inc.

July 30th, 2009 Sanofi-Aventis pays Merck $4B for share in MerialPARIS — Pharmaceuticals company Sanofi-Aventis SA said Thursday it has agreed to pay $4 billion in cash to U.S. drugmaker Merck & Co.

August 28th, 2009 Sanofi-Aventis plans to close Kansas City plantNEW YORK — Drug developer Sanofi-Aventis says it will close its Kansas City, Mo., plant by 2012, citing a decline in demand for products made at the site. The plant makes solid dose forms of oral medications, including the seasonal allergy medication Allegra-D.

June 3rd, 2009 Merck may sell animal drug assets before mergerWHITEHOUSE STATION, N.J. — Drugmaker Merck & Co.

June 17th, 2009 Sanof-Aventis to give pandemic flu vaccine to WHOTRENTON, N.J. — The drugmaker Sanofi-Aventis says it will donate millions of doses of swine flu vaccine to the World Health Organization for poor countries.

June 17th, 2009 Sanofi-Aventis to give pandemic flu vaccine to WHOTRENTON, N.J. — French drugmaker Sanofi-Aventis plans to donate millions of doses of swine flu vaccine to the World Health Organization for use in poor countries, Chief Executive Christopher Viehbacher said Wednesday.

June 12th, 2009 Drugmakers rush to produce a swine flu vaccineLONDON — With swine flu now an official pandemic, the race is on among drugmakers to produce a vaccine. GlaxoSmithKline said Thursday after the World Health Organization declared a global flu epidemic that it would be ready within weeks to begin large-scale vaccine production.

July 21st, 2009 Drug industry, Pfizer lead in health lobbyingWASHINGTON — The drug industry's trade group and one of the nation's biggest pharmaceutical companies reported spending more money than other health care organizations on lobbying in the second quarter of this year. With the fight over President Barack Obama's effort to revamp the nation's health care system escalating, the Pharmaceutical Research and Manufacturers of America said it spent $6.2 million lobbying in April, May and June, according to reports to Congress that were due Monday.

July 6th, 2009 KUALA LUMPUR - The Parent-Teacher Association of a secondary school in Malaysia is seeking the help of authorities to investigate claims that the school principal held karaoke sessions with female students at the girls' hostel. According to SM Tok Janggut Parent-Teacher Association chairman Datuk Mohd Jelani Jaafar, they had received numerous complaints on the matter, and some of them were from the teachers themselves.

July 16th, 2009 Sotomayor can get by on justice's payWASHINGTON — Supreme Court nominee Sonia Sotomayor says she's lived on a judge's salary for 17 years, and she can, in her words, "suffer through more of it." Supreme Court justices make a little more than $200,000 a year. Sotomayor was responding Thursday to questions from Republican Sen.